| Ytd | 28.71% | |
| 1y | -7.66% |
| Open | 9.54 | Prev Close | 9.60 | Low | 9.14 | High | 9.54 | Mkt Cap | 280.77M |
| Vol | 90.81K | Avg Vol | 256.02K | EPS | -5.78 | P/E | N/A | Forward P/E | -5.54 |
| Beta | 0.63 | Short Ratio | 15.83 | Inst. Own | 27.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 9.09 | 200-d Avg | 7.63 | 1yr Est | 38.17 |
RNAC News
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the a
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected i
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a str
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthe
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maint
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Des
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-0
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology c
Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “C
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC)
FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “C
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zac
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the
Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase
Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for aut
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volu
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Tr
FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the
Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and
Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutr
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the
Cartesian Therapeutics, Inc. (NASDAQ: RNAC - Get Free Report) has been assigned an average rating of
Applied Therapeutics (NASDAQ: APLT - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get
Cartesian Therapeutics, Inc. (NASDAQ: RNAC - Get Free Report) has received an average rating of "Mod
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the
Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalim
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC)
Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for
BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology c
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the